659 COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases

MLA

Drew Rasco, et al. “659 COM701 plus Nivolumab Demonstrates Preliminary Antitumor Activity and Immune Modulation of Tumor Microenvironment in Patients with Metastatic MSS-CRC and Liver Metastases.” Regular and Young Investigator Award Abstracts, Nov. 2022. EBSCOhost, https://doi.org/10.1136/jitc-2022-sitc2022.0659.

APA

Drew Rasco, Ecaterina Dumbrava, Manish Sharma, Dale Shepard, Daniel Vaena, Gini Fleming, Bartosz Chmielowski, Erika Hamilton, Ryan Sullivan, Kyriakos Papadopoulos, Amita Patnaik, Eran Ophir, Gady Cojocaro, Chet Bohac, Adeboye Adewoye, Manish Patel, & Michael Overman. (2022). 659 COM701 plus nivolumab demonstrates preliminary antitumor activity and immune modulation of tumor microenvironment in patients with metastatic MSS-CRC and liver metastases. Regular and Young Investigator Award Abstracts. https://doi.org/10.1136/jitc-2022-sitc2022.0659

Chicago

Drew Rasco, Ecaterina Dumbrava, Manish Sharma, Dale Shepard, Daniel Vaena, Gini Fleming, Bartosz Chmielowski, et al. 2022. “659 COM701 plus Nivolumab Demonstrates Preliminary Antitumor Activity and Immune Modulation of Tumor Microenvironment in Patients with Metastatic MSS-CRC and Liver Metastases.” Regular and Young Investigator Award Abstracts, November. doi:10.1136/jitc-2022-sitc2022.0659.